Skip to main content
SpringerLink
Log in

The use of DMARDs is significantly delayed in the treatment of rheumatoid arthritis,

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Decision Resources Inc.Initiation of DMARDS as First-Line Therapy is Significantly Delayed in the Treatment of Rheumatoid Arthritis. Media Release: 14 Nov 2007. Available from: URL: http://www.decisionresources.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The use of DMARDs is significantly delayed in the treatment of rheumatoid arthritis,. Pharmacoecon. Outcomes News 543, 10 (2007). https://doi.org/10.2165/00151234-200705430-00030

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200705430-00030

Keywords

Search

Navigation